PLGA-Rhodamine from PolySciTech used for development of inhalable siRNA therapy for respiratory therapy

 

Researchers at University of Napoli Federico II, Berlin Institute of Health, Ludwig-Maximilians-Universität München, University of Campania Luigi Vanvitelli, University of Milano, and University of British Columbia used PLGA-Rhodamine B (cat# AV011 https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AV011#h) from PolySciTech : Akina, Inc. (www.PolySciTech.com) combined with ionizable lipids to form nanoparticles for siRNA delivery through inhaled formulations. This research holds promise to improve respiratory therapy. Read more: Brusco, Susy, Ersilia Villano, Teresa Silvestri, Amar J. Azad, Muge Molbay, Ivana d'Angelo, Agnese Miro et al. "Lipid@ polymer hybrid nanoparticles for efficient siRNA transport across the lung barriers: Mechanistic insights into the role of Ionizable lipids." Journal of Colloid and Interface Science (2026): 140683. https://www.sciencedirect.com/science/article/pii/S002197972600860X

“Building on growing evidence that ionizable lipids improve RNA delivery, in this work, we developed ionizable lipid/poly(lactic-co-glycolic acid) hybrid nanoparticles (iLipid@PLGA hNPs), consisting in a PLGA core modified at surface with either 1,2-dioleoyloxy-3-dimethylaminopropane (DODMA), 1,2-dioleoyl-3-trimethylammonium-propane (DODAP), or the branched-tail proprietary amino lipid ALC0315. iLipid@PLGA hNPs were engineered to meet key requirements for inhalation. Thorough physicochemical characterization revealed how the choice of ionizable lipid influences pH responsiveness, surface composition, and architecture of iLipid@PLGA hNPs. In vitro studies demonstrated effective siRNA encapsulation, adjustable release kinetics, and poor interactions with mucus components, as assessed by combined UV–Vis, Dynamic Light Scattering, and Small Angle X-ray Scattering analyses. Confocal microscopy analysis of A549 cells transfected with iLipid@PLGA hNPs showed reduced colocalization of AlexaFluor647-labeled siRNA with lysosomes over time, suggesting enhanced endosomal escape in the case of DODMA@PLGA hNPs. Functional validation using GAPDH-targeting siRNA (siGAPDH) confirmed cellular uptake and gene silencing in normal human bronchial epithelial (NHBEs) cells, confirming the superior performance of DODMA@PLGA hNPs. Finally, representative fluorescently labeled DODMA@PLGA hNPs successfully diffused across a 3D air–liquid interface (ALI) cell model, simulating the human bronchial epithelial barrier. These findings highlight the successful integration of ionizable lipids into polymeric nanoparticles, establishing iLipid@PLGA hNPs as versatile and efficient carriers for siRNA therapeutics. This breakthrough supports their continued development in respiratory nanomedicine and in the local treatment of lung diseases.”

Benchtop to Bedside with MidWestGMP https://www.akinainc.com/midwestgmp/

Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/

Ashland-TM Polymer Products: https://akinainc.com/polyscitech/products/ashland/

PrecisionGelTM from Vivos https://akinainc.com/polyscitech/products/vivos/